Degarelix

Evidence Level: L5

Predicted Indications: 10

Degarelix

Pharmacist Assessment Report

Degarelix: From Its Approved Use to Hypertrichosis (Prediction Only)

One-Sentence Summary

Degarelix is a GnRH receptor antagonist marketed in Canada as FIRMAGON. The approved indication text was not available in the data compiled for this report. The TxGNN model predicts it may be effective for hypertrichosis, but no clinical trials and no publications currently support this prediction, so it rests on the TxGNN model (deep learning) score alone.

Quick Overview

Item	Content
Original Indication	Not available in the compiled data
Predicted New Indication	Hypertrichosis (disease)
TxGNN Prediction Score	0.9999
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs: 2 of 2)
Number of DINs	2 (marketed: 2)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Degarelix is a GnRH receptor antagonist. It suppresses LH and FSH, which lowers gonadal androgen and estrogen levels. Detailed mechanism-of-action data were not available in the compiled data, so this description is based on the drug’s known class.

In theory, suppressing androgens could reduce androgen-dependent hair growth, such as hirsutism-type hypertrichosis. However, most forms of hypertrichosis are not androgen-dependent: they are congenital, drug-induced, or part of a syndrome. The mechanistic link is therefore weak. The very high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. It is not backed by clinical or literature evidence.

Other predicted indications (all L5, no trials or literature):

Rank	Predicted Indication	Score	Assessment
2	Ambras type hypertrichosis universalis congenita	0.9998	Not driven by gonadal androgens (TRPS1 regulation); no clear rationale
3	Syndrome with Dandy-Walker malformation	0.9998	Structural developmental disorder; no plausible mechanism
4	Malformation syndrome with odontal/periodontal component	0.9998	Likely a similarity the model learned between related diseases, not biological evidence
5	Isolated genetic hair shaft abnormality	0.9998	Structural, not hormonally mediated
6	Allergic urticaria	0.9997	Urticaria is a known adverse event of the drug, so this is more likely a safety signal
7	Cold urticaria	0.9986	No mechanistic pathway; histamine-releasing potential argues against use
8	Familial male-limited precocious puberty	0.9984	Driven by activating LHCGR mutations downstream of the pituitary, so GnRH antagonism is not expected to help
9	Central precocious puberty 1	0.9967	Most biologically plausible, since GnRH-axis suppression is the established principle; remains a research question only
10	Familial isolated trichomegaly	0.9965	Not known to be androgen-driven

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02337029	FIRMAGON	Not available	Not available
02337037	FIRMAGON	Not available	Not available

Cytotoxicity

Item	Content
Cytotoxicity Classification	Hormonal therapy (GnRH antagonist), not a conventional cytotoxic agent
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Contraindication signals from the knowledge graph (these come from drug-disease graph edges, not from label text): long QT syndrome, familial long QT syndrome, torsades de pointes, liver disease, gallbladder disease, potassium deficiency disease.
Drug Interactions (100 interactions found; examples shown):
- Major: cisapride, dolasetron
- Moderate: clarithromycin, levofloxacin, ondansetron, granisetron, palonosetron, famotidine, loperamide, and several laxatives and bowel-preparation agents (bisacodyl, picosulfuric acid, polyethylene glycol, lactulose, magnesium citrate, magnesium hydroxide)
- Minor: metronidazole
- Many of these interactions are likely related to QT prolongation and electrolyte disturbance.
Adverse-event signal: urticaria and injection-site reactions have been associated with degarelix, which argues against the urticaria predictions.

Package insert warnings and contraindications were not available. Please refer to the package insert for full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The top prediction has no clinical trials or literature (Evidence Level L5), and its mechanistic link is weak because most hypertrichosis is not androgen-driven. Of all the predictions, only central precocious puberty is mechanistically coherent, and it is already treated with established GnRH agonists. It should be handled as a research question, not a development candidate.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
Approved indication text and dosage form for the two DINs
Mechanism of action data from DrugBank
A literature and trial search focused on central precocious puberty and androgen-dependent hirsutism
Pediatric safety data, plus a QT and electrolyte risk assessment, before any new-population use is considered
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.